Adze Biotechnology is a clinical-stage oncolytic immunotherapy platform company with active programs in melanoma, breast cancer, and liver cancer. Our proprietary oncolytic backbone is designed for both systemic and intra-tumoral delivery, and we can vary IO payloads at will. We are actively seeking investors for our $30mm B round to fund our multiple clinical programs with early data readouts expected in late 2026.